| The use of aromatase inhibitors in adjuvant therapy for early breast cancer. | |
| | |
MedLine Citation:
|
PMID: 16273366 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Clinical evidence supporting the use of aromatase inhibitors (AIs) in adjuvant therapy for hormone-sensitive early breast cancer (EBC) has grown rapidly over the past few years and is reviewed in this article. The results of two studies-the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial and the Breast International Group (BIG) 1-98 trial-support the use of AIs as primary adjuvant therapy for EBC, with significantly prolonged disease-free survival, time to recurrence, and time to distant recurrence for both anastrozole and letrozole over tamoxifen. Furthermore, anastrozole has an established beneficial risk:benefit ratio compared with tamoxifen with mature data over the full 5-year recommended treatment period. For women who have already received 2-3 years of tamoxifen, switching studies with anastrozole [the Italian Tamoxifen Anastrozole (ITA) trial and the Austrian Breast and Colorectal Cancer Study Group (ABCSG) 8/Arimidex-Nolvadex (ARNO 95) trial] and exemestane [the Intergroup Exemestane Study (IES)] have also shown that 5 years of primary adjuvant tamoxifen therapy is not optimal and that switching to an AI should be considered. Finally, for those women who have completed 5 years of tamoxifen, based on the results of the MA 17 trial, extended adjuvant treatment with letrozole should be considered. Although no sequencing data are available yet, current evidence suggests that an AI should be the adjuvant treatment of choice over tamoxifen, and anastrozole is the only AI with mature adjuvant data to date. |
| | |
Authors:
|
Walter Jonat; Felix Hilpert; Nicolai Maass |
Related Documents
:
|
17268816 - A novel dual-target steroid sulfatase inhibitor and antiestrogen: sr 16157, a promising... 15908126 - A comparison of fulvestrant and the third-generation aromatase inhibitors in the second... 18087606 - Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding... 19115686 - Tamoxifen in women with breast cancer and mammographic density. 8017726 - Screening for ovarian cancer. 23138176 - Ovarian cancer stem cells: working towards the root of stemness. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: 56 Suppl 1 ISSN: 0344-5704 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 2005 Nov |
Date Detail:
|
Created Date: 2005-11-25 Completed Date: 2006-02-23 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: Germany |
Other Details:
|
Languages: eng Pagination: 32-8 Citation Subset: IM |
Affiliation:
|
Klinik fur Gynakologie und Gerburtshilfe, University of Kiel, 24105, Kiel, Germany. jonat@e-mail.uni-kiel.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aromatase Inhibitors
/
therapeutic use* Breast Neoplasms / diagnosis, drug therapy* Chemotherapy, Adjuvant / methods Female Humans Randomized Controlled Trials as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Aromatase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Function of nuclear sex hormone receptors in gene regulation.
Next Document: Hormone treatment for prostate cancer: current issues and future directions.